Today: 11 June 2026
Rocket Lab stock slips after rally as insider sale filing surfaces; Neutron timing in focus
5 January 2026
1 min read

Rocket Lab stock slips after rally as insider sale filing surfaces; Neutron timing in focus

New York, January 5, 2026, 11:35 EST — Regular session

Rocket Lab Corp shares slipped 0.7% to $75.43 by 11:09 a.m. EST on Monday, after closing at $75.99 on Friday. The stock traded between $71.31 and $75.70 and sits roughly 5% below its 52-week high of $79.83.

The wobble follows a sharp re-rating since Rocket Lab said it had won an $816 million prime contract from the U.S. Space Development Agency to design and manufacture 18 satellites for the agency’s Tracking Layer Tranche 3 program. The company said the award includes a $806 million base plus up to $10.45 million in options.

A Form 144 filing also drew attention after it showed Rocket Lab Chief Operating Officer Frank Klein planned to sell up to 100,000 shares under a Rule 10b5-1 trading plan. Form 144 is a notice insiders file before selling certain securities, while a 10b5-1 plan sets pre-arranged trades to reduce the risk of trading on non-public information.

The satellite award is part of the Pentagon’s push for proliferated constellations — large networks of smaller satellites — to improve missile warning and tracking. “The addition of these satellites will achieve near-continuous global coverage for missile warning and tracking,” said Gurpartap “GP” Sandhoo, the agency’s acting director, in a statement cited by the Los Angeles Business Journal, which also reported Lockheed Martin and Northrop Grumman were among other recipients in the broader tranche.

Cantor Fitzgerald on Monday reiterated an Overweight rating and a $72 price target on Rocket Lab, flagging the SDA win and what it sees as a heavy 2026 catalyst calendar. The broker said the contract about doubles Rocket Lab’s contracted backlog, which it put at roughly $1.1 billion as of the third quarter of 2025, and said the first flight of the company’s Neutron rocket is expected in the first half of 2026.

Rocket Lab last told investors it generated $155 million of revenue in the third quarter and forecast fourth-quarter revenue of $170 million to $180 million, with GAAP gross margin of 37% to 39%. It also updated the Neutron schedule, saying the rocket is set to arrive at its Launch Complex 3 site in the first quarter of 2026, with a first launch after that pending qualification testing and acceptance.

But the stock’s steep climb has amplified execution risk. Any slip in Neutron testing, slower conversion of backlog into booked revenue, or margin pressure from ramping production could sharpen drawdowns after a run that has pushed the shares near their highs.

Traders now look for follow-through on timing — and for the next set of numbers. Nasdaq’s earnings calendar estimates Rocket Lab will report next results around Feb. 26.

Stock Market Today

  • Top Software Stocks Set for Rally in Second Half, Says BofA
    June 11, 2026, 11:15 AM EDT. Bank of America (BofA) has identified leading software stocks poised for a significant rally in the second half of the year. While specific companies were not detailed, BofA's outlook highlights growth potential in the tech sector amid evolving market conditions. Investors are closely watching software firms as demand for digital solutions continues to expand, driven by cloud computing and enterprise software trends. This bullish stance from a major financial institution underscores confidence in software stocks as key components of portfolio growth strategies moving forward.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks
Previous Story

BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Next Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

Go toTop